# Sacituzumab Govitecan In TNBC

Source: https://onco.cc/trials/nct04230109/  
OnCo record `nct04230109` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of sacituzumab govitecan and pembrolizumab in triple-negative breast cancer, run by Massachusetts General Hospital, now recruiting.

## Summary

Sacituzumab Govitecan In TNBC. ClinicalTrials.gov record last updated 2026-07-17: recruiting. Enrollment is planned at 239 participants. Primary completion is estimated at 2028-10. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Sacituzumab Govitecan, Pembrolizumab. Registered primary measures: Pathological complete response(pCR) rate with sacituzumab govitecan.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Also known as: NeoSTAR
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT04230109
- Phase: 2
- Setting: Sacituzumab Govitecan In TNBC
- Sponsor: Massachusetts General Hospital
- Enrolled: 239

## Notes

- ClinicalTrials.gov record last updated 2026-07-17: recruiting. Enrollment is planned at 239 participants. Primary completion is estimated at 2028-10. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

## Sources

- ClinicalTrials.gov NCT04230109: https://clinicaltrials.gov/study/NCT04230109

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04230109.json